Maxalt

Rizatriptan, the active ingredient in Maxalt, is a Triptan presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks with or without aura in adults and provides rapid relief of migraine symptoms such as headache, nausea, and sensitivity to light.

GNH USA supplies Maxalt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assured manufacturing and distribution networks that meet EU regulatory standards and ensuring product integrity throughout the supply chain.

Rizatriptan is a Triptan used in the acute management of migraine.

Migraine with aura: alleviates headache and associated neurological symptoms. Migraine without aura: provides rapid pain relief and reduces nausea. Acute migraine attack: reduces severity of headache, photophobia and phonophobia.

Rizatriptan may cause a range of adverse reactions.

Common Side Effects: - Dizziness or light‑headedness. - Fatigue or drowsiness. - Dry mouth or mild nausea. - Tingling sensations in the fingers or toes. - Chest discomfort or pressure. - Transient visual disturbances.

Serious or Rare Side Effects: - Coronary artery vasospasm leading to chest pain or myocardial ischemia. - Serotonin syndrome, especially when combined with other serotonergic agents. - Severe hypertension or hypertensive crisis. - Allergic reactions such as rash, angioedema, or anaphylaxis. - Stroke or transient ischemic attack. - Severe hepatic dysfunction.

Before prescribing Rizatriptan, consider the following precautions.

Assess cardiovascular risk: evaluate history of coronary artery disease, uncontrolled hypertension or cerebrovascular disorders. Avoid use with ergotamine derivatives: concurrent use can cause severe vasospasm. Do not exceed recommended dose: follow prescriber instructions and avoid repeat dosing within 24 hours. Use caution in patients with uncontrolled hypertension: monitor blood pressure closely. Avoid driving or operating machinery if dizziness occurs. Store at ambient temperature: keep in the original container, protect from moisture and excessive heat.

Rizatriptan may interact with several medication classes.

Major Interactions (Avoid): - Ergotamine or ergot derivatives: risk of additive vasoconstriction and severe coronary events. - Monoamine oxidase inhibitors (MAOIs): increased risk of serotonin syndrome. - Other triptans: additive vasoconstrictive effects may precipitate cardiovascular complications.

Moderate Interactions (Monitor Closely): - SSRIs, SNRIs, or other serotonergic agents: potential for serotonin syndrome, monitor for symptoms. - Beta‑blockers: may reduce the therapeutic response of Rizatriptan. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase plasma concentrations of Rizatriptan, consider dose adjustment.